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Abstract
Background: Cardiac fibrosis occurs with normal aging, but the extent of this process and its
effect on cardiac function is unknown. Fibrosis in the nonhypertensive elderly patient is thought to
be due to decreased degradation, and not increased deposition, of collagen. The cause of this
decreased degradation is unknown. Athletes commonly develop cardiac hypertrophy, and recent
evidence has linked long-term physical activity to the development of interstitial myocardial fibrosis.
Whether this exercise-induced fibrosis occurs regularly, or only in genetically predisposed
individuals, is unknown.
Case presentation: We present the case of an elderly, nonhypertensive athlete who died
suddenly of sepsis. Autopsy demonstrated foci of fibrosis throughout the right and left ventricle
and significant narrowing of the left ventricular cavity. The findings may be secondary to aging,
athletic activity or an undiagnosed medical condition.
Conclusion:  The true incidence and importance of age- and exercise-associated myocardial
fibrosis is an area for future research.
Background
Myocardial fibrosis occurs in a number of pathological
processes, most commonly hypertension. Other disease
states capable of producing cardiac fibrosis include hyper-
eosinophilia, scleroderma, sarcoidosis, radiation and
drug effects, viral myocarditis and inherited genetic muta-
tions. Normal aging is also associated with a certain
degree of interstitial fibrosis, but the degree of this non-
pathological fibrosis is yet to be determined. Animal
models of aging have shown alterations in collagen depo-
sition [1], and studies involving human subjects and post-
mortem examinations have documented increased fibro-
sis in the conduction system [2] and atria [3] with aging,
but the true incidence of global myocardial fibrosis that
can be expected in a healthy, normotensive elderly patient
is not known.
Case presentation
The patient was a 73-year-old healthy African American
female with no significant medical history. Notably, she
was an avid athlete and power lifter, participated regularly
in aerobic activity and traveled frequently. She presented
initially with a 2-day history of sore throat and fever and
acute onset of mental status changes. Upon arrival at the
hospital she was found to be febrile, hypertensive, tachy-
cardic and tachypneic and to have an elevated white
blood cell count of 15.2 K/ul. Physical examination
revealed no obvious source of infection, and EKG showed
tachycardia but otherwise normal electrical activity. The
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patient rapidly decompensated and died despite resuscita-
tive efforts. Pre-mortem blood samples were later found
to be positive for group A beta-hemolytic Streptococci.
Postmortem examination of the patient's medical records
revealed no significant disease history. She had a favora-
ble cholesterol profile, with total cholesterol of 183 mg/
dl, triglycerides 66, LDL 98 and HDL 72. There was no his-
tory of hypertension or evidence of cardiac disease and no
history of eosinophilia.
Autopsy was performed and revealed no pathological
processes acutely related to death, including no signs of
localized infection as the source of bacteremia. The
patient was found to have cardiomegaly with a cardiac
weight of 365 grams, left ventricular wall thickness of 1.8
mm and markedly decreased chamber volume. Histologi-
cal examination showed wide distribution of interstitial
myocardial fibrosis (Figures 1, 2 and 3). Fibrosis was
present throughout the right and left ventricles in an
inconsistent pattern and was more prevalent in the
endomyocardium. The largest foci of fibrosis measured
approximately 4 mm in greatest diameter, and approxi-
mately 25% of the myocardium was involved by some
degree of fibrosis. A single foci of inflammatory infiltrate
was noted, but was not located near an area of fibrosis.
Microfiber disarray and septal hypertrophy were absent.
The coronary arteries were notably patent with minimal
atherosclerosis.
Discussion
While the cardiac fibrosis in this patient was not the
immediate cause of death, the findings of a diffuse distri-
bution of patchy fibrosis and myocardial hypertrophy in
a patient with no history of hypertension, hyperlipidemia
or cardiac disease are puzzling. Some degree of fibrosis is
expected in the healthy elderly myocardium, but likely to
a smaller degree than seen in the present case. Myocardial
hypertrophy in the elderly is most commonly a response
to reduced vascular compliance, but in the absence of
hypertension the degree of ventricular wall thickening
and loss of chamber volume seen in this patient would
not be expected. This patient's history of athletic activity,
Histological section of myocardium with areas of patchy  interstitial fibrosis associated with myocyte hypertrophy  (high magnification) Figure 3
Histological section of myocardium with areas of 
patchy interstitial fibrosis associated with myocyte 
hypertrophy (high magnification).
Histological section of myocardium (low magnification) Figure 1
Histological section of myocardium (low magnifica-
tion). Some areas showed only myocyte hypertrophy.
Histological section of myocardium with areas of patchy  interstitial fibrosis associated with myocyte hypertrophy  (high magnification) Figure 2
Histological section of myocardium with areas of 
patchy interstitial fibrosis associated with myocyte 
hypertrophy (high magnification). Fibrosis was present 
in both ventricular walls, and no single large focus of fibrosis 
was identified. Inflammation was minimal and the coronary 
arteries showed no atherosclerotic disease.Diagnostic Pathology 2008, 3:12 http://www.diagnosticpathology.org/content/3/1/12
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including power lifting, would support the finding of
myocardial hypertrophy. Athletes are known to have
physiological cardiac hypertrophy, but this is not usually
associated with the development of fibrosis or chamber
narrowing.
Fibrosis within the myocardium may be due to a variety
of different pathological processes, and the pattern of
fibrosis provides clues as to the underlying cause. Hyper-
tensive cardiac fibrosis is classically perivascular with infil-
tration into the surrounding interstitium. A single large
focus of fibrosis is consistent with remote myocardial inf-
arction; hypereosinophilia and idiopathic restrictive car-
diomyopathy produce fibrosis ranging from patchy
subendocardial disease to diffuse full-thickness involve-
ment. Radiation-induced fibrosis is often more severe in
the right ventricle.
Aging and myocardial fibrosis
Changes associated with aging are difficult to separate
from those due to diseases prevalent in the elderly, most
notably hypertension. Histological changes seen in the
non hypertensive aging heart include increased myocyte
necrosis and apoptosis [4] and an altered deposition of
types I and III collagen [1]. An autopsy study of 230 non-
cardiac patients demonstrated increased fibrosis and fat
within the cardiac conduction system of elderly patients
[2]. An age-related increase in right atrial fibrosis and
decrease in nerve plexus population has also been demon-
strated [3]. Burns [5] reported increased cardiac fibrosis,
significantly more prominent in the posterior left ventri-
cle, with aging. Klima [5] reported increased interstitial
fibrosis related to aging that was independent of other car-
diac diseases. A comparison of endomyocardial biopsies
from elderly and young patients found increased cell
diameter and nuclear area (a sign of increased protein pro-
duction) and an increased deposition of lipid and lipofus-
cin with age [6].
While hypertensive patients show increased deposition of
collagen, nonhypertensive aging patients develop
increased interstitial collage levels due to decreased degra-
dation [7,8]. Antihypertensive therapy prevents left ven-
tricular fibrosis, which is secondary to pressure overload,
but is ineffective in preventing right ventricular fibrosis
[9], supporting the concept of disease-independent car-
diac fibrosis in elderly patients.
Biochemical mechanisms of myocardial fibrosis
Hypertensive cardiac fibrosis is related to the direct effects
of pressure overload and to circulating hormones. Perivas-
cular fibrosis and cardiac fibroblast activation correlate
with increased activity of the renin-angiotensin-aldoster-
one system (RAAS) and elevated serum mineralocorti-
coids; this fibrosis is preventable with angiotensin-
converting enzyme (ACE) inhibitors or spironolactone
[10,11]. In heart failure, elevations in aldosterone and
angiotensin II result from ischemia of the kidney and
adrenal gland, as well as increased salt intake. Weber [12]
reported local production of angiotensin II within the
myocardium, suggesting a role for intrinsic myocardial
activation of ACE secondary to ischemia.
The molecular activity of angiotensin II and adrenergic
stimulation involve the extracellular-signal-related
kinases (ERK1/2), p38 and Jun N-terminal kinase (JNK)
[13,14], leading to fibroblast activation. Inflammation is
also involved in hypertensive collagen deposition;
Nicoletti [14] emphasized the role of inflammation in the
development of cardiac fibrosis. Angiotensin II activates
monocytes [15]. Infiltration of inflammatory cells has
been documented in animal models of the hypertensive
heart [14,16,17]. The inflammatory infiltrate is initially
perivascular and later spreads interstitially, following the
same pattern as that of collagen deposition [16]. Myocar-
dial remodeling in the development of congestive heart
failure has also been attributed to reactive oxygen species
(ROS) production by the mitochondrial, xanthine oxi-
dase, nitric oxide synthetase and NADPH oxidase path-
ways [18,19].
Myocardial fibrosis that occurs with normal aging should
not be dependent upon the RAAS or inflammatory medi-
ators, as neither of these systems are activated in the
healthy elderly patient. Even in the absence of overt
hypertension, arterial vascular walls loose compliance
with age, resulting in some degree of pressure overload
with normal aging. Whether this age-related pressure
overload is severe enough to cause cardiac ischemia and
fibrosis is unknown. Aging rats show increased left ven-
tricular weight, extracellular collagen and collagen cross-
linking, and decreased mRNA collagen expression [20].
This supports the theory that an age-related increase in
cardiac fibrosis is not secondary to increased production,
but instead is due to decreased destruction of existing col-
lagen.
Exercise induced changes in the myocardium
It is well documented that athletes frequently develop left
ventricular hypertrophy [21], but this is not thought to be
associated with fibrosis, as it regresses upon cessation of
physical activity [22]. Lindsay and Dunn [23] questioned
the validity of the common theory that exercise-induced
hypertrophy is entirely physiological, based on the fact
that veteran athletes often do not experience complete res-
olution of ventricular hypertrophy [24,25], suggesting a
mechanism other than pure myocyte hypertrophy. Ath-
letes are prone to the development of EKG abnormalities
[25]. Following endurance exercises, athletes have eleva-
tions in serum markers of myocyte damage and reductionDiagnostic Pathology 2008, 3:12 http://www.diagnosticpathology.org/content/3/1/12
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in diastolic and systolic function [26], although these
changes return to baseline within 24 hours. In the evalua-
tion of 45 veteran endurance athletes [23], echocardio-
graphic evidence of left ventricular hypertrophy and
elevations in serum markers of collagen synthesis, degra-
dation and inhibition of degradation were documented,
suggesting the presence of cardiac fibrosis related to long-
term athletic activity. Whyte et al. [27] reported the case of
a 57 year old athlete who died suddenly while running a
marathon. Autopsy revealed biventricular fibrosis, left
ventricular hypertrophy and reduction of left ventricular
chamber volume.
Conclusion
The true incidence and degree of age-related myocardial
fibrosis is unknown; both animal and human models
have documented its occurrence. Whether these age-
related changes are due primarily to the diseases more fre-
quently seen in the elderly, namely hypertension and
inflammation, or arose de novo due to decreased collage
breakdown is also uncertain. More recent reports of exer-
cise-induced fibrosis raise the question of late pathologi-
cal consequences of physical activity. Hypertension-
related myocardial fibrosis is at least partly preventable
with pharmacotherapy. Further understanding of the
mechanisms associated with age- and exercise-induced
fibrosis may likewise lead to the discovery of chemical
pathways that can be pharmacologically altered, allowing
for the prevention of cardiac dysfunction associated with
fibrotic change.
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